What are the best anticoagulation options in terms of cost-benefit-risk for oncology patients with venous thrombotic disease and risk of gastrointestinal bleeding due to gastric tumor?
Direct evidence supports LMWH as the preferred anticoagulation option for oncology patients with gastric tumors due to its lower bleeding risk compared to direct oral anticoagulants.
Authors
- Tripdatabase
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-18
- DOI
- https://doi.org/10.5281/zenodo.24345265
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00